CA2257803C - Elements et procedes pour traiter ou prevenir les mycoses pathogenes - Google Patents

Elements et procedes pour traiter ou prevenir les mycoses pathogenes Download PDF

Info

Publication number
CA2257803C
CA2257803C CA002257803A CA2257803A CA2257803C CA 2257803 C CA2257803 C CA 2257803C CA 002257803 A CA002257803 A CA 002257803A CA 2257803 A CA2257803 A CA 2257803A CA 2257803 C CA2257803 C CA 2257803C
Authority
CA
Canada
Prior art keywords
rapamycin
rapalog
rapalogs
antifungal
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002257803A
Other languages
English (en)
Other versions
CA2257803A1 (fr
Inventor
Dennis A. Holt
Terence P. Keenan
Timothy P. Clackson
Leonard Rozamus
Wu Yang
Michael Z. Gilman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Gene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Gene Therapeutics Inc filed Critical Ariad Gene Therapeutics Inc
Priority claimed from PCT/US1997/012584 external-priority patent/WO1998002441A2/fr
Publication of CA2257803A1 publication Critical patent/CA2257803A1/fr
Application granted granted Critical
Publication of CA2257803C publication Critical patent/CA2257803C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Dérivés de rapamycine et leurs utilisations antifongiques. On décrit aussi les éléments et les procédés qui se prêtent à l'identification de dérivés de rapamycine ayant une action antifongique non-immunosuppressive.
CA002257803A 1996-07-12 1997-07-14 Elements et procedes pour traiter ou prevenir les mycoses pathogenes Expired - Lifetime CA2257803C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US2162496P 1996-07-12 1996-07-12
US60/021,624 1996-07-12
US4830797P 1997-05-30 1997-05-30
US60/048,307 1997-05-30
US5035397P 1997-06-20 1997-06-20
US60/050,353 1997-06-20
PCT/US1997/012584 WO1998002441A2 (fr) 1996-07-12 1997-07-14 Elements et procedes pour traiter ou prevenir les mycoses pathogènes

Publications (2)

Publication Number Publication Date
CA2257803A1 CA2257803A1 (fr) 1998-01-22
CA2257803C true CA2257803C (fr) 2008-12-02

Family

ID=27361689

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257803A Expired - Lifetime CA2257803C (fr) 1996-07-12 1997-07-14 Elements et procedes pour traiter ou prevenir les mycoses pathogenes

Country Status (2)

Country Link
JP (1) JP2002514165A (fr)
CA (1) CA2257803C (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006067862A1 (fr) * 2004-12-22 2006-06-29 The Kitasato Institute Substances actives k03-0132 et procédé de production de celles-ci
EP2948145A1 (fr) 2013-01-28 2015-12-02 Pola Pharma Inc. Composition pharmaceutique destinées à des maladies provoquées par des microorganismes pathogènes tels qu'aspergillus
WO2014185542A1 (fr) 2013-05-17 2014-11-20 Pola Pharma Inc. Composition pharmaceutique pour traiter une vaginite ou une pneumonie
CA3103282A1 (fr) * 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Analogues de la rapamycine et leurs utilisations
WO2020128861A1 (fr) * 2018-12-18 2020-06-25 Novartis Ag Dérivés de rapamycine
WO2020194209A1 (fr) 2019-03-26 2020-10-01 Novartis Ag Dérivés de rapamycine contenant du 1,1-dioxyde d'isothiazolidine et du 1,4-butane-butane et leurs utilisations
IL293549A (en) 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and their uses
CN112057425A (zh) * 2020-09-30 2020-12-11 严鹏科 一种雷帕霉素制剂及其制备方法

Also Published As

Publication number Publication date
JP2002514165A (ja) 2002-05-14
CA2257803A1 (fr) 1998-01-22

Similar Documents

Publication Publication Date Title
AU735648B2 (en) Materials and method for treating or preventing pathogenic fungal infection
JP6831259B2 (ja) アミノ酸１および３で修飾されたシクロスポリン類似体分子
CA2244363C (fr) Derives synthetiques de rapamycine utilises comme agents de multimerisation de proteines chimeres a domaines derives de l'immunophiline
KR100585348B1 (ko) 중수소화된 시클로스포린 유사체 및 면역조절제로서 그의용도
Mayer et al. Synthesis of new didemnin B analogs for investigations of structure/biological activity relationships
CA2257803C (fr) Elements et procedes pour traiter ou prevenir les mycoses pathogenes
GB2212499A (en) Cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
CA2115221A1 (fr) Peptides aminomethylenes utilises comme immunosuppresseurs
EP1212331A1 (fr) Analogues d'epirapamycine-28
HUT73418A (en) Process for preparing rapamycin carbonate esters and pharmaceutical compositions of immunosuppressive activity containing said compounds
HUT74675A (en) C-22-ring stabilized rapamycin derivatives and pharmaceutical compositions containing them
EP2970301B1 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2014505035A5 (fr)
EP0444897A1 (fr) Nouvelles analogues immunosuppressives de la cyclosporine avec des acides aminées modifiées dans la position 8
JP2014511894A (ja) 抗結核化合物としてのテトラヒドロピラゾロ［１，５‐ａ］ピリミジン
WO1998056785A1 (fr) Derives de pyrazole
EA038414B1 (ru) Гетеробициклические соединения и их применение для лечения туберкулеза
JPH06234735A (ja) 免疫抑制剤としてのスルホンアミドアミノメチレン誘導体
WO1999012933A2 (fr) Derives de pyrrolopyrrolone en tant qu'inhibiteurs de neutrophile elastase
ES2551923T3 (es) Derivados de pirazolina y su uso como moduladores selectivos de receptores de andrógenos
El Rouby et al. Comparison of the properties of the CsA analogs monoacetyl CyC (o-acetyl-threonine2 cyclosporin) and methyl-alanyl CsA (N-methyl-L-alanyl6 cyclosporin); monoacetyl cyclosporin is immunosuppressive without binding to cyclophilin
Papageorgiou et al. Derivatives of cyclosporin at position 2 as probes for cyclophilin
Shao Stereoisomeric design and synthesis of peptidomimetic building blocks and biologically active molecules
Uto Studies toward the total synthesis and stereochemical assignment of Lissoclinum metabolites: Trunkamide A and bistramide C

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170714